PemvidutidevsVitamin B12

Pemvidutide (ALT-801) is a once-weekly subcutaneous dual GLP-1 and glucagon receptor agonist, mechanistically similar to mazdutide and survodutide but with a distinct molecular design and a primary development focus on metabolic dysfunction-associated steatohepatitis (MASH) alongside obesity. The dual mechanism combines appetite suppression with enhanced energy expenditure and direct hepatic fat mobilisation.

The GLP-1 receptor component drives the established central appetite suppression through hypothalamic and brainstem signalling, slows gastric emptying, and stimulates glucose-dependent insulin secretion. The glucagon receptor agonism component is what differentiates pemvidutide from pure GLP-1 drugs — glucagon binding in hepatocytes activates adenylyl cyclase and protein kinase A, driving up fatty acid beta-oxidation and ketogenesis while reducing de novo lipogenesis. This directly mobilises stored hepatic triglycerides for energy use rather than continued storage, addressing the core pathology of MASH. In adipose tissue and beyond, glucagon signalling also raises whole-body energy expenditure through thermogenic and futile-cycle mechanisms.

The receptor potency ratio is balanced so that glucagon-driven hepatic glucose output is offset by GLP-1-driven insulinotropic effects, yielding net glycemic improvement alongside enhanced fat oxidation. Phase 2b results in obesity demonstrated approximately 15.6% mean body weight loss at 48 weeks, and parallel MASH trials showed significant reductions in liver fat content alongside improvements in fibrosis markers. Phase 3 trials in both obesity and MASH are now underway, positioning pemvidutide as Altimmune's lead asset and a competitor to mazdutide and survodutide in the dual GLP-1/glucagon class.

Vitamin B12 (cobalamin) is a large organometallic molecule with a cobalt ion at its center, coordinated within a corrin ring. It is the most structurally complex vitamin and the only one containing a metal ion. Humans cannot synthesize B12 — it is produced exclusively by certain bacteria and archaea, and enters the human diet through animal products or bacterial fermentation. Absorption requires intrinsic factor (produced by gastric parietal cells), which binds B12 in the ileum for receptor-mediated endocytosis via the cubam receptor complex.

B12 functions as a cofactor for two essential enzymes. Methionine synthase (MS) uses methylcobalamin (methylB12) to catalyze the transfer of a methyl group from methyltetrahydrofolate (methyl-THF) to homocysteine, producing methionine and regenerating tetrahydrofolate (THF). This reaction sits at the intersection of two critical pathways: methionine is converted to S-adenosylmethionine (SAM), the universal methyl donor for DNA methylation, histone modification, neurotransmitter synthesis, and hundreds of other methylation reactions; and THF regeneration is essential for folate cycling and de novo nucleotide synthesis (required for DNA replication). B12 deficiency traps folate as methyl-THF ('methyl trap'), blocking DNA synthesis and causing megaloblastic anemia — red blood cell precursors cannot replicate their DNA properly, producing abnormally large, non-functional cells.

Methylmalonyl-CoA mutase uses adenosylcobalamin (adenosylB12) in mitochondria to convert methylmalonyl-CoA to succinyl-CoA, a key step in the catabolism of odd-chain fatty acids, branched-chain amino acids, and cholesterol. Deficiency causes methylmalonic acid accumulation, which is toxic to neurons and contributes to the peripheral neuropathy, subacute combined degeneration of the spinal cord, and cognitive decline seen in B12 deficiency. The neurological damage occurs because myelin synthesis requires both SAM-dependent methylation reactions (for phospholipid synthesis) and proper fatty acid metabolism (for myelin lipid composition), both of which depend on B12. Neurological damage from severe B12 deficiency can become irreversible if not treated promptly, which is why injectable B12 (which bypasses absorption barriers) is preferred for deficiency treatment.